ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy

• Artiva reported positive early clinical data for its AlloNK cell therapy in patients with difficult-to-treat rheumatoid arthritis and other autoimmune diseases.
• The U.S. Food and Drug Administration has aligned with the biotech firm on a single Phase 3 registrational trial.
• Artiva reported a loss of $0.95 per share, compared to estimates of a loss of $0.86 per share.

Shares of Artiva Biotherapeutics (ARTV) pared early premarket gains on Friday, after a discounted $300 million public offering and a wider-than-expected first-quarter (Q1) loss weighed on sentiment even as the biotech firm announced promising clinical results for its rheumatoid arthritis and autoimmune disease therapy.

On Friday, Artiva reported a net loss of $23.5 million, or $0.95 per share, wider than analysts’ expectations of a loss of $0.86 per share, according to Fiscal.ai data.

ARTV’s Phase 2 Trial Shows Significant Symptom Improvement

Artiva reported positive early clinical data for its AlloNK cell therapy in patients with difficult-to-treat rheumatoid arthritis (RA) and other autoimmune diseases. In the ongoing Phase 2a trial, 71% of refractory RA patients with at least six months of follow-up achieved an ACR50 response, a key measure showing significant symptom improvement.

The company said no patients relapsed or required additional treatments during follow-up. Artiva also highlighted favorable safety and tolerability results for the AlloNK plus Rituximab drug treatment regimen.

No cases of cytokine release syndrome (CRS), neurotoxicity (ICANS), or treatment discontinuations were reported, supporting the potential for outpatient use in community rheumatology clinics.

More than 70 autoimmune patients have been treated with AlloNK across over 40 active clinical sites globally. The U.S. Food and Drug Administration (FDA) has aligned with Artiva on a single Phase 3 registrational trial comparing AlloNK plus Rituximab against Rituximab alone in about patients. The company plans to begin the trial in the second half of 2026.

ARTV’s $300M Offering

Separately, the biotech firm announced the pricing of an underwritten public offering that is expected to raise about $300 million in gross proceeds. The company is set to sell nearly 23.9 million shares of common stock at $11.52 per share, along with pre-funded warrants to purchase about 2.17 million additional shares for certain investors. This represents a 9% discount from the stock’s Thursday closing price.

Artiva said all securities in the offering are being sold directly by the company to support the development of its autoimmune disease therapies.

What Does Retail Think Of ARTV?

Retail sentiment for ARTV on Stocktwits remained in the ‘extremely bullish’ territory over the past 24 hours, while message volumes were ‘high.’

One user called the Phase 3 approval “solid news” and expected the stock to rally after breaking past $16.

The stock has gained more than 190% so far in 2026.

Read also: RKLB Stock Is Back In Rally Mode After Q1 Earnings – And Retail Traders Want $100 Next

For updates and corrections, email newsroom[at]stocktwits[dot]com.